Table 2.
Morphometric and echocardiographic characteristics of mice treated for 4 weeks with AAV9-MCS or AAV9-miR-106b~25.
| AAV9-MCS | AAV9-miR-106b~25 | |
|---|---|---|
| n | 5 | 5 |
| BW (g) | 29.4 ± 0.5 | 24.3 ± 1.7 |
| LV mass (mg) | 79 ± 7 | 121 ± 26* |
| LV mass/BW (mg/g) | 2.7 ± 0.2 | 4.8 ± 0.6* |
| IVSd (mm) | 0.68 ± 0.03 | 0.91 ± 0.08* |
| IVSs (mm) | 1.05 ± 0.04 | 1.28 ± 0.09 |
| LVIDd (mm) | 3.75 ± 0.12 | 4.08 ± 0.08* |
| LVIDs (mm) | 2.50 ± 0.14 | 2.78 ± 0.19 |
| LVPWd (mm) | 0.84 ± 0.09 | 0.85 ± 0.08 |
| LVPWs (mm) | 1.07 ± 0.06 | 1.09 ± 0.07 |
| EF (%) | 70 ± 3 | 66 ± 5 |
| FS (%) | 33 ± 2 | 31 ± 3 |
Data are expressed as means ± SEM.
BW body weight, LV left ventricular, IVSd interventricular septal thickness at end-diastole, IVSs interventricular septal thickness at end-systole, LVIDd left ventricular internal dimension at end-diastole, LVIDs left ventricular internal dimension at end-systole, LVPwd left ventricular posterior wall thickness at end-diastole, LVPws left ventricular posterior wall thickness at end-systole, EF ejection fraction, FS fractional shortening, E/A Doppler E/A ratio.
*Indicates P < 0.05 vs sham group subjected to treatment with a control antagomir.
#Indicates P < 0.05 vs experimental group.